{
    "nct_id": "NCT05904886",
    "official_title": "A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma",
    "inclusion_criteria": "* Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology/cytology or clinically by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic participants\n* Disease that is not amenable to curative surgical and/or locoregional therapies\n* No prior systemic treatment for locally advanced or metastatic and/or unresectable HCC\n* Measurable disease according to RECIST v1.1\n* ECOG Performance Status of 0 or 1 within 7 days prior to randomization\n* Child-Pugh Class A within 7 days prior to randomization\n* Adequate hematologic and end-organ function\n* Female participants of childbearing potential must be willing to avoid pregnancy within 5 months after the final dose of atezolizumab, within 6 months after the final dose of bevacizumab, and within 90 days after the final dose of tiragolumab/placebo\n* Male participants with a female partner of childbearing potential or pregnant female partner must remain abstinent or use a condom during the treatment period and for 6 months after the final dose of bevacizumab and for 90 days after the final dose of tiragolumab/placebo to avoid exposing the embryo.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Pregnancy or breastfeeding within 5 months after the final dose of atezolizumab, within 6 months after the final dose of bevacizumab, and within 90 days after the final dose of tiragolumab/placebo\n* Prior treatment with CD137 agonists or immune checkpoint blockade therapies\n* Treatment with investigational therapy within 28 days prior to initiation of study treatment\n* Treatment with locoregional therapy to liver within 28 days prior to initiation of study treatment, or non-recovery from side effects of any such procedure\n* Treatment with systemic immunostimulatory agents\n* Treatment with systemic immunosuppressive medication\n* Untreated or incompletely treated esophageal and/or gastric varices with bleeding or that are at high risk for bleeding\n* A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment\n* Active or history of autoimmune disease or immune deficiency\n* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan\n* History of malignancy other than HCC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death\n* Mixed histology or other subtypes/variants of HCC, including, but not limited to, known liver adenocarcinoma, fibrolamellar HCC, sarcomatoid HCC, other rare HCC variant, or mixed cholangiocarcinoma and HCC\n* Co-infection with hepatitis B virus (HBV) and hepatitis C virus (HCV)\n* Acute Epstein-Barr virus (EBV) infection or known or suspected chronic active EBV infection\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases.",
    "miscellaneous_criteria": ""
}